Ricky McCormick, DO
Family Medicine · Independence, IANPI 1427055375
Payments from drug & device makers
Across 112 payments — averaging $12.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$225
- Johnson & Johnson$213
- AstraZeneca$197
- Pfizer$132
- Amgen$109
- Novartis$95
- plus $463 from 14 others
What the payments were for
- Food & beverage$1,428100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 20 | $225 |
| Johnson & Johnson | 23 | $213 |
| AstraZeneca | 8 | $197 |
| Pfizer | 14 | $132 |
| Amgen | 7 | $109 |
| Novartis | 6 | $95 |
| Boehringer Ingelheim | 6 | $85 |
| Novo Nordisk | 5 | $72 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $51 |
| Astellas Pharma US Inc | 3 | $44 |
| Vapotherm Inc | 1 | $31 |
| Lilly USA, LLC | 2 | $28 |
| Merck | 2 | $27 |
| Sanofi-aventis U.S. LLC | 2 | $26 |
| Insulet Corporation | 2 | $26 |
| Tactile Systems Technology Inc | 1 | $17 |
| Genentech USA, Inc. | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Mylan Specialty L.p. | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
How this compares
$1,433 in reported general payments places this provider in the 85th percentile of 1,357 family medicine providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FirdapseAmifampridine Phosphate | 13 | $737,645 |
| MounjaroTirzepatide | 125 | $146,127 |
| EliquisApixaban | 138 | $82,133 |
| JardianceEmpagliflozin | 73 | $60,717 |
| OzempicSemaglutide | 55 | $51,035 |
| XareltoRivaroxaban | 70 | $46,395 |
| TradjentaLinagliptin | 60 | $36,949 |
| TrulicityDulaglutide | 30 | $36,366 |
| MyrbetriqMirabegron | 58 | $33,952 |
| FarxigaDapagliflozin Propanediol | 54 | $30,033 |
| GlyxambiEmpagliflozin/Linagliptin | 29 | $24,841 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $21,457 |
| SynjardyEmpagliflozin/Metformin Hcl | 17 | $18,864 |
| Bydureon BciseExenatide Microspheres | 22 | $18,284 |
| LinzessLinaclotide | 32 | $16,562 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $28 | $182,493155 claims |
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi, Synjardy, Combivent Respimat | $85 | $158,730214 claims |
| PfizerEliquis | $132 | $82,133138 claims |
| Novo NordiskOzempic | $72 | $51,03555 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $197 | $47,94192 claims |
| Johnson & JohnsonXarelto | $213 | $46,39570 claims |
| Astellas Pharma US IncMyrbetriq | $44 | $33,95258 claims |
| AbbVieLinzess | $225 | $16,56232 claims |
| MerckJanumet, Dulera | $27 | $10,90324 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,357 family medicine providers in Iowa.
Other family medicine in Independence
- Nicholas GoetschWaterloo$4.1M
- James PoockWaterloo$1.5M
- Jennifer KayCouncil Bluffs$613K
- Nicholas BechtoldSioux City$584K
- Kirk PetersonHuxley$576K
- Stephen HarrisonClinton$249K
- Sharon SteenBelle Plaine$241K
- Carlos Alarcon SchroderJohnston$237K
- Thomas RossDes Moines$170K
- Yogesh ShahDes Moines$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.